Total submissions: 5
Submitter | RCV | SCV | Clinical significance | Condition | Last evaluated | Review status | Method | Comment |
---|---|---|---|---|---|---|---|---|
ARUP Laboratories, |
RCV001123271 | SCV000604405 | uncertain significance | Autosomal recessive nonsyndromic hearing loss 3 | 2023-09-25 | criteria provided, single submitter | clinical testing | |
Laboratory for Molecular Medicine, |
RCV000506047 | SCV000967255 | likely benign | not specified | 2018-02-27 | criteria provided, single submitter | clinical testing | p.Arg3465Gln in exon 65 of MYO15A: This variant is not expected to have clinical significance because the amino acid residue at position 3465 is not conserved t hrough species with 3 mammals (marmoset, squirrel monkey, star-nosed mole) havin g a glutamine (Gln) at this position. This variant has also been identified in 44/125630 European chromosomes, including 1 homozygous individual, by the Genome Aggregation Database (gnomAD, http://gnomad.broadinstitute.org; dbSNP rs1997835 06). ACMG/AMP Criteria applied: BP4_Strong. |
Illumina Laboratory Services, |
RCV001123271 | SCV001282094 | uncertain significance | Autosomal recessive nonsyndromic hearing loss 3 | 2017-08-01 | criteria provided, single submitter | clinical testing | This variant was observed as part of a predisposition screen in an ostensibly healthy population. A literature search was performed for the gene, cDNA change, and amino acid change (where applicable). Publications were found based on this search. However, the evidence from the literature, in combination with allele frequency data from public databases where available, was not sufficient to rule this variant in or out of causing disease. Therefore, this variant is classified as a variant of unknown significance. |
Labcorp Genetics |
RCV002056908 | SCV002342364 | likely benign | not provided | 2024-01-18 | criteria provided, single submitter | clinical testing | |
Ce |
RCV002056908 | SCV004142410 | uncertain significance | not provided | 2023-09-01 | criteria provided, single submitter | clinical testing | MYO15A: PM2, BP4 |